Industry & Policy News

[Endothelial Cell News, Organoid News] Professor Milica Radisic has been awarded the 2023 Humboldt Research Award from the Alexander von Humboldt Foundation. “This is a huge honour. The award is one of the most prestigious international recognitions a scientist can get,” say Radisic, who holds the Canada Research Chair in Organ-on-a-Chip Engineering.

[Essex Bio-Technology Ltd] Essex Bio-Technology Ltd announced that a Phase I/II clinical trial of EB12-20145P, a recombinant anti-VEGF humanised monoclonal antibody injection jointly developed by the Group and Shanghai Henlius Biotech, Inc., has been completed in patients with wet age-related macular degeneration. The results of this study demonstrated the good safety and tolerability of EB12-20145P.

[Science Insider] Although below the rate of biomedical inflation, it is far more generous than a corresponding House of Representatives bill that would slash NIH’s budget by 6%.

[Citius Pharmaceuticals, Inc.] Citius Pharmaceuticals, Inc. announced that the US FDA has issued a Complete Response Letter regarding the Company's Biologics License Application seeking approval for denileukin diftitox.

[Invectys, Inc.] Invectys, Inc. announced the US FDA has granted Fast Track designation to its revolutionary product, IVS-3001, a CAR-T cell immunotherapy that targets the rarely exploited immune checkpoint and tumor-specific antigen known as HLA-G.

[ISS National Lab] Researchers at Emory University will leverage the International Space Station National Laboratory to continue examining how microgravity affects the growth and function of cardiomyocytes as they mature into tissue-like structures.